Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Company Deals

Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline

Fineline Cube Dec 15, 2025
Company Deals

Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing

Fineline Cube Dec 15, 2025
Company Deals

Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline

Fineline Cube Dec 15, 2025
Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Fineline Cube Dec 14, 2025
Policy / Regulatory

China Healthcare Fund Settlement Reform Targets 3% Ratio by 2028

Fineline Cube Dec 15, 2025
Company Drug

Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline

Fineline Cube Dec 15, 2025
Company Drug

GSK’s Nucala Wins CHMP Nod for COPD in Europe

Fineline Cube Dec 15, 2025
Company Drug

Shanghai Henlius Secures NMPA Approval for Phase II/III HLX22 HER2 Trials, Pioneering Novel Epitope ADC Combination in Breast Cancer

Fineline Cube Dec 10, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...

Company Deals

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

Fineline Cube Dec 10, 2025

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) has granted Nanjing King-friend Biochemical Pharmaceutical Co., Ltd....

Company Drug

FDA Waskyra WAS Gene Therapy First Cell-Based

Fineline Cube Dec 10, 2025

The US Food and Drug Administration (FDA) approved Waskyra (etuvetidigene autotemcel) as the first cell‑based...

Company Drug

FDA Omisirge Severe Aplastic Anemia First HSCT

Fineline Cube Dec 10, 2025

The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem...

Company Deals

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Fineline Cube Dec 10, 2025

Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership...

Company Deals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Fineline Cube Dec 10, 2025

Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly‑owned subsidiary Nova Pneuma Inc. (NPI)...

Company Deals

Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market

Fineline Cube Dec 9, 2025

Zhaoke Ophthalmology (HKG: 6622) announced it has granted TSH Biopharm (TW-8432) exclusive rights to register,...

Company Drug

Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval

Fineline Cube Dec 9, 2025

Kexing Biopharm (SHA: 688136) announced that its GB10 injection has received approval from China’s National...

Company Drug

Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy

Fineline Cube Dec 9, 2025

Ignis Therapeutics announced that cenobamate tablets received marketing approval from China’s National Medical Products Administration...

Company Drug

Ignis Therapeutics Solriamfetol NMPA Approval Targets OSA Sleepiness

Fineline Cube Dec 9, 2025

Ignis Therapeutics announced that Solriamfetol Hydrochloride Tablets received approval from China’s National Medical Products Administration...

Company Drug

Abbisko ABSK043 NSCLC Combo Shows 71% Disease Control at ESMO Asia

Fineline Cube Dec 8, 2025

Abbisko Cayman Limited (HKG: 2256) announced preliminary results from the dose escalation phase of the...

Company Drug

Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR

Fineline Cube Dec 8, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase 1/2 data for LBL-034 in relapsed/refractory multiple...

Company Drug

Junshi Biosciences roconkibart psoriasis NMPA Acceptance

Fineline Cube Dec 8, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announces that the National Medical Products...

Company Drug

CSPC SYH2069 GLP-1/GIP Dual Agonist Wins FDA Nod for Obesity

Fineline Cube Dec 8, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1/GIP receptor dual-biased agonist...

Company Drug

Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive

Fineline Cube Dec 8, 2025

Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative...

Company Medical Device

Balance Medical ePTFE Pericardial-Membrane Gets NMPA Nod, Ends Import Reliance

Fineline Cube Dec 8, 2025

Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) announced that its expanded polytetrafluoroethylene (ePTFE) pericardial...

Company Deals

Shanghai Pharma X842 Deal Termination with Sinorda

Fineline Cube Dec 8, 2025

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced the termination of its...

Company Drug

Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval

Fineline Cube Dec 8, 2025

Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval...

Company Drug

Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted

Fineline Cube Dec 8, 2025

Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products...

Company Deals Medical Device

Mirxes XtalPi AI Platform Targets Asian GI Cancers

Fineline Cube Dec 8, 2025

Mirxes Holding Company Limited (HKG: 2629) announced it has entered into a memorandum of understanding...

Posts pagination

1 2 3 4 … 597

Recent updates

  • Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline
  • GSK’s Nucala Wins CHMP Nod for COPD in Europe
  • Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio
  • Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity
  • Innovent’s Mazdutide Wins Macau Approval for Weight Management
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline

Company Drug

GSK’s Nucala Wins CHMP Nod for COPD in Europe

Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Company Drug

Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.